458 related articles for article (PubMed ID: 33055258)
21. The role of the gut microbiome in colonization resistance and recurrent
Seekatz AM; Safdar N; Khanna S
Therap Adv Gastroenterol; 2022; 15():17562848221134396. PubMed ID: 36425405
[TBL] [Abstract][Full Text] [Related]
22. Changes in microbial ecology after fecal microbiota transplantation for recurrent C. difficile infection affected by underlying inflammatory bowel disease.
Khanna S; Vazquez-Baeza Y; González A; Weiss S; Schmidt B; Muñiz-Pedrogo DA; Rainey JF; Kammer P; Nelson H; Sadowsky M; Khoruts A; Farrugia SL; Knight R; Pardi DS; Kashyap PC
Microbiome; 2017 May; 5(1):55. PubMed ID: 28506317
[TBL] [Abstract][Full Text] [Related]
23. Fecal microbiota transplantation as therapy for recurrent Clostridioides difficile infection is associated with amelioration of delirium and accompanied by changes in fecal microbiota and the metabolome.
Gotoh K; Sakaguchi Y; Kato H; Osaki H; Jodai Y; Wakuda M; Také A; Hayashi S; Morita E; Sugie T; Ito Y; Ohmiya N
Anaerobe; 2022 Feb; 73():102502. PubMed ID: 34896553
[TBL] [Abstract][Full Text] [Related]
24. The success of fecal microbial transplantation in
Park H; Laffin MR; Jovel J; Millan B; Hyun JE; Hotte N; Kao D; Madsen KL
Gut Microbes; 2019; 10(6):676-687. PubMed ID: 30866714
[No Abstract] [Full Text] [Related]
25. Fecal Microbiota Transplantation Influences Procarcinogenic Escherichia coli in Recipient Recurrent Clostridioides difficile Patients.
Nooij S; Ducarmon QR; Laros JFJ; Zwittink RD; Norman JM; Smits WK; Verspaget HW; Keller JJ; Terveer EM; Kuijper EJ;
Gastroenterology; 2021 Oct; 161(4):1218-1228.e5. PubMed ID: 34126062
[TBL] [Abstract][Full Text] [Related]
26. Fecal microbiota transplantation for treatment of recurrent C. difficile infection: An updated randomized controlled trial meta-analysis.
Hui W; Li T; Liu W; Zhou C; Gao F
PLoS One; 2019; 14(1):e0210016. PubMed ID: 30673716
[TBL] [Abstract][Full Text] [Related]
27. The evaluation of fecal microbiota transplantation vs vancomycin in a Clostridioides difficile infection model.
Xu Q; Zhang S; Quan J; Wu Z; Gu S; Chen Y; Zheng B; Lv L; Li L
Appl Microbiol Biotechnol; 2022 Oct; 106(19-20):6689-6700. PubMed ID: 36085529
[TBL] [Abstract][Full Text] [Related]
28. Microbiota dynamics in patients treated with fecal microbiota transplantation for recurrent Clostridium difficile infection.
Song Y; Garg S; Girotra M; Maddox C; von Rosenvinge EC; Dutta A; Dutta S; Fricke WF
PLoS One; 2013; 8(11):e81330. PubMed ID: 24303043
[TBL] [Abstract][Full Text] [Related]
29. Microbiota-based Therapies Clostridioides difficile infection that is refractory to antibiotic therapy.
Mehta SR; Yen EF
Transl Res; 2021 Apr; 230():197-207. PubMed ID: 33278650
[TBL] [Abstract][Full Text] [Related]
30. Risk of Clostridium difficile Infection with Systemic Antimicrobial Therapy Following Successful Fecal Microbiota Transplant: Should We Recommend Anti-Clostridium difficile Antibiotic Prophylaxis?
Allegretti JR; Kao D; Phelps E; Roach B; Smith J; Ganapini VC; Kassam Z; Xu H; Fischer M
Dig Dis Sci; 2019 Jun; 64(6):1668-1671. PubMed ID: 30632052
[TBL] [Abstract][Full Text] [Related]
31. Fecal microbiota transplantation for recurrent Clostridium difficile infection in hematopoietic stem cell transplant recipients.
Webb BJ; Brunner A; Ford CD; Gazdik MA; Petersen FB; Hoda D
Transpl Infect Dis; 2016 Aug; 18(4):628-33. PubMed ID: 27214585
[TBL] [Abstract][Full Text] [Related]
32. Fecal Microbiota Transplantation and Microbial Therapeutics for the Treatment of Clostridioides difficile Infection in Pediatric Patients.
Bernard R; Hourigan SK; Nicholson MR
J Pediatric Infect Dis Soc; 2021 Nov; 10(Supplement_3):S58-S63. PubMed ID: 34791396
[TBL] [Abstract][Full Text] [Related]
33. Prevention of recurrent Clostridioides difficile infection: A systematic review of randomized controlled trials.
Madoff SE; Urquiaga M; Alonso CD; Kelly CP
Anaerobe; 2020 Feb; 61():102098. PubMed ID: 31493500
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects on luminal and mucosal microbiota and commonly acquired taxa in faecal microbiota transplantation for recurrent Clostridium difficile infection.
Jalanka J; Mattila E; Jouhten H; Hartman J; de Vos WM; Arkkila P; Satokari R
BMC Med; 2016 Oct; 14(1):155. PubMed ID: 27724956
[TBL] [Abstract][Full Text] [Related]
35. Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection.
Millan B; Park H; Hotte N; Mathieu O; Burguiere P; Tompkins TA; Kao D; Madsen KL
Clin Infect Dis; 2016 Jun; 62(12):1479-1486. PubMed ID: 27025836
[TBL] [Abstract][Full Text] [Related]
36. Diluted Fecal Community Transplant Restores Clostridioides difficile Colonization Resistance to Antibiotic-Perturbed Murine Communities.
Lesniak NA; Tomkovich S; Henry A; Taylor A; Colovas J; Bishop L; McBride K; Schloss PD
mBio; 2022 Aug; 13(4):e0136422. PubMed ID: 35913161
[TBL] [Abstract][Full Text] [Related]
37. Faecalibacterium prausnitzii increases following fecal microbiota transplantation in recurrent Clostridioides difficile infection.
Björkqvist O; Rangel I; Serrander L; Magnusson C; Halfvarson J; Norén T; Bergman-Jungeström M
PLoS One; 2021; 16(4):e0249861. PubMed ID: 33836037
[TBL] [Abstract][Full Text] [Related]
38. Long-term beneficial effect of faecal microbiota transplantation on colonisation of multidrug-resistant bacteria and resistome abundance in patients with recurrent Clostridioides difficile infection.
Nooij S; Vendrik KEW; Zwittink RD; Ducarmon QR; Keller JJ; Kuijper EJ; Terveer EM;
Genome Med; 2024 Feb; 16(1):37. PubMed ID: 38419010
[TBL] [Abstract][Full Text] [Related]
39. Changes in IgA-targeted microbiota following fecal transplantation for recurrent
Huus KE; Frankowski M; Pučić-Baković M; Vučković F; Lauc G; Mullish BH; Marchesi JR; Monaghan TM; Kao D; Finlay BB
Gut Microbes; 2021; 13(1):1-12. PubMed ID: 33382360
[TBL] [Abstract][Full Text] [Related]
40. Longitudinal microbiome analysis of single donor fecal microbiota transplantation in patients with recurrent Clostridium difficile infection and/or ulcerative colitis.
Mintz M; Khair S; Grewal S; LaComb JF; Park J; Channer B; Rajapakse R; Bucobo JC; Buscaglia JM; Monzur F; Chawla A; Yang J; Robertson CE; Frank DN; Li E
PLoS One; 2018; 13(1):e0190997. PubMed ID: 29385143
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
